Climb Bio Inc CLYM
10.36 USD -0.51 (-4.69%)
Regular-session close
9.62 -0.74 -7.16%
After hours · Nov 13, 5:16 PM ET
10.19 Day range 10.99
1.64 52-week range 17.84
- YTD
- +159.00%
- 1 year
- +454.01%
News
benzinga.com Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27 Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $25 to $27.
benzinga.com Climb Bio Q3 EPS $(0.18) Beats $(0.20) Estimate Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 5.26 percent increase over losses of $(0.19) per…- benzinga.com Climb Bio To Present New Clinical Data For Budoprutug In Immune Thrombocytopenia At 68th ASH Annual Meeting And Exposition Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for…
benzinga.com Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study…- benzinga.com Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval~70% reduction in Gd-IgA1 at 12 weeks~33-day half-lifeNAVIGATE-2 Phase 2 trial enrolling, with initial data…
benzinga.com Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28 Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $28.
benzinga.com Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026 Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for…
benzinga.com Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25 Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $18 to $25.
benzinga.com Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.- benzinga.com HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.
- benzinga.com B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30 B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.
benzinga.com BTIG Maintains Buy on Climb Bio, Raises Price Target to $32 BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.
benzinga.com Baird Maintains Outperform on Climb Bio, Raises Price Target to $25 Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.
benzinga.com Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.- benzinga.com HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $24 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $24.
- benzinga.com Truist Securities Maintains Buy on Climb Bio, Raises Price Target to $25 Truist Securities analyst Danielle Brill maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $17 to $25.
- benzinga.com Climb Bio Q2 EPS $(0.18) Beats $(0.21) Estimate Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 38.46 percent decrease over losses of $(0.13)…
benzinga.com Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC, SRAD, AIAI, ALOY, and…
benzinga.com This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Wall Street analysts have changed their outlook on top names, with new coverage and price targets. See the latest analyst ratings and opinions.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com GE Vernova To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session